Finding ways to make brain tumors more responsive to radiation treatment
Exploiting cell fate transition to overcome radiation resistance in glioblastoma
This study is looking at why some glioblastoma brain tumors don’t respond well to radiation therapy, and it aims to find new ways to make the treatment more effective by using special techniques to target the stubborn cells in the tumor.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10895462 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain tumor that is often resistant to radiation therapy. The team is investigating the molecular characteristics of glioblastoma stem-like cells to understand why some tumors resist treatment. By using advanced techniques like CRISPR gene editing, they aim to identify specific targets that can be manipulated to enhance the effectiveness of radiation therapy. The goal is to combine these new targets with standard radiation treatment to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are undergoing or have undergone radiation therapy.
Not a fit: Patients with other types of brain tumors or those who are not receiving radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting molecular pathways in glioblastoma, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Sulman, Erik — New York University School of Medicine
- Study coordinator: Sulman, Erik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.